NEWS
Tollys presents new data at OTS 2022, demonstrating anti-tumor activity of TL-532
Results highlight specificity of TLR3-agonist TL-532, that induces lifelong anti-tumor auto-vaccination and reverses resistance to immune checkpoint inhibitors
TOLLYS : la phase clinique bientôt en vue (La Gazette du Laboratoire – Juillet 2022)
Un produit très prometteur et une phase clinique prévue en 2024
AACR 2022: Tollys releases new preclinical data demonstrating lifelong potent anti-tumor immunity of TL-532
These results confirm two new properties for TL-532, which showed proof-of-concept of inducing tumor cell death by apoptosis and reversing resistance to immune checkpoint inhibitors in previous studies.
Tollys and Gustave Roussy enter into new research agreement
Prof. Guido Kroemer’s team, from Gustave Roussy, will test Tollys’ specific TLR3 agonist, TL-532, to restore deficient chemotherapeutic responses in the context of FPR1 deficiency. FPR1 deficiency affects 30% of world population and is associated with precocious manifestation of breast, colorectal, esophageal, head and neck carcinomas.
Tollys accelerates development of TLR3 agonist candidates for intravenous administration in immuno-oncology
Based on the strong preclinical data collected to date with locally administered TL-532, Tollys is accelerating and expanding its internal and collaborative R&D activities on TLR3 agonist candidates designed for intravenous administration and antibody-drug-conjugates.
Tollys
Cutting-Edge Cancer Immunotherapy
Office
60F avenue Rockefeller
69008 Lyon, FRANCE